Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

VISTA Expression Is Associated With A Favorable Prognosis In Patients With High-grade Serous Ovarian Cancer

Liju Zong, Yuncan Zhou, M. Zhang, J. Chen, Y. Xiang
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Blockading programmed death ligand 1 (PD-L1) shows promising results in patients with some cancers, but not in those with ovarian cancer. V-domain Ig suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint protein that suppresses T cell activation. This study aimed to investigate the expression and clinical significance of VISTA in ovarian cancer as well as its relationship with PD-L1. VISTA and PD-L1 levels in 146 ovarian cancer samples were assessed using immunohistochemistry. We investigated the association between VISTA and other clinicopathological variables, including survival. The associations between the VISTA-encoding C10orf54 gene, other immune checkpoints, and survival were analyzed. VISTA was detected in 51.4% of all samples and 46.6% of PD-L1-negative samples; it was expressed in 28.8%, 35.6%, and 4.1% of tumor cells (TCs), immune cells (ICs), and endothelial cells, respectively. Furthermore, VISTA expression was associated with pathologic type and PD-L1 expression. Moreover, VISTA expression in TCs, but not in ICs, was associated with prolonged progression-free and overall survival in patients with high-grade serous ovarian cancer. The expression of C10orf54 mRNA was associated with prolonged overall survival and immune escape-modulating genes. These results showed that VISTA expression in ovarian tumor cells was associated with a favorable prognosis in patients with high-grade serous ovarian cancer; however, additional studies are required to better understand the expression and role of VISTA in ovarian cancer.
This paper references
10.1007/s00262-017-1968-0
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma
L. Wu (2017)
10.1172/JCI74589
Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.
D. Flies (2014)
10.1073/pnas.1811067116
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
J. Blando (2019)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1016/j.ygyno.2016.03.008
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
J. R. Webb (2016)
10.1073/pnas.0611533104
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J. Hamanishi (2007)
10.1016/j.ygyno.2018.11.017
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
A. Varga (2019)
10.1007/s00262-018-2227-8
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
S. Xie (2018)
10.1038/nm.4308
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
10.1089/omi.2011.0118
clusterProfiler: an R package for comparing biological themes among gene clusters.
Guangchuang Yu (2012)
10.1073/pnas.1420370112
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
10.1038/s41598-018-27521-y
Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
Ádám Nagy (2018)
10.1186/s13045-018-0684-3
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
Zihai Li (2018)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
10.7150/jca.28134
Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets
Junjun Yang (2019)
10.5858/arpa.2018-0043-OA
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Karina Kulangara (2019)
10.1158/2159-8290.CD-12-0095
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
E. Cerami (2012)
10.1007/s11864-017-0504-y
Immunotherapy in Gynecologic Cancers: Are We There Yet?
J. B. Pakish (2017)
10.1080/2162402X.2018.1469594
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L. Wang (2018)
2018) spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human nonsmall cell lung cancer
F Villarroel-Espindola (2018)
10.1007/s00262-018-2169-1
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski (2018)
10.1126/scisignal.2004088
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
J. Gao (2013)
10.1111/imr.12525
Immunoregulatory functions of VISTA
Elizabeth Nowak (2017)
10.1158/1078-0432.CCR-17-2542
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
F. Villarroel‐Espíndola (2017)
10.1097/PGP.0000000000000494
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES)
A. Mills (2019)
10.1158/0008-5472.CAN-13-1504
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
10.1038/s41416-018-0313-5
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.1111/imm.13001
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
10.1186/s12885-018-4435-1
VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
M. Zhang (2018)
10.1080/2162402X.2017.1293215
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Christine Böger (2017)
10.1111/his.13882
PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia
Liju Zong (2019)
Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
J Hamanishi (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar